Research and Markets: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/7twtgs/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects.

Drug profiles/records featured in the report undergo periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD)
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics

Companies Mentioned:

• DURECT Corporation
• Eli Lilly and Company
• Dainippon Sumitomo Pharma
• Taisho Pharmaceutical
• NeuroDerm
• Samyang Holdings Corporation
• Pfizer
• Impax Laboratories
• Shire
• Collegium Pharmaceutical
• Bionomics Limited
• Chelsea Therapeutics International
• Hisamitsu Pharmaceutical
• Theravance
• Arbor Pharmaceuticals
• Curemark
• Supernus Pharmaceuticals
• Intra-Cellular Therapies
• Tris Pharma
• Neos Therapeutics
• KemPharm
• Otsuka Holdings
• Reviva Pharmaceuticals
• Amarantus Bioscience Holdings
• Mnemosyne Pharmaceuticals
• Alcobra
• Signature Therapeutics
• P2D Bioscience
• AbbVie

For more information visit http://www.researchandmarkets.com/research/7twtgs/attention_deficit